Phenotypes associated with this allele
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Pkd1tm1.2Djmp mutation
(0 available);
any
Pkd1 mutation
(154 available)
|
|
|
mortality/aging
|
|
• all mice exhibit embryonic lethality
|
Allelic
Composition |
Pkd1tm1.2Djmp/Pkd1+
|
|
Genetic
Background |
involves: 129P2/OlaHsd * FVB/N |
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Pkd1tm1.2Djmp mutation
(0 available);
any
Pkd1 mutation
(154 available)
|
|
|
renal/urinary system
|
|
• mice exhibit a higher proliferation index for precystic tubular epithelial cells than wild-type mice
|
cellular
|
|
• mice exhibit a higher proliferation index for precystic tubular epithelial cells than wild-type mice
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Pkd1tm1.1Djmp mutation
(0 available);
any
Pkd1 mutation
(154 available)
Pkd1tm1.2Djmp mutation
(0 available);
any
Pkd1 mutation
(154 available)
Tg(Cdh16-cre/ERT2)F427Djmp mutation
(0 available)
|
|
|
renal/urinary system
|
|
• adult mice treated with tamoxifen for 3 to 5 months exhibit a 5- to 20-fold increase in proliferation index for precystic tubular epithelial cells compared to wild-type mice
|
|
|
• mice exhibit 1-5 cysts after 1 months of treatment with tamoxifen beginning at 3 months of age and about 10 cysts after 3 months that are bilateral and in the cortex and medulla
• mice develop massive cysts 1 month after exposure to tamoxifen by breast feeding beginning at 4 days of age that arise from distal parts of the nephron and are uromodulin-positive
|
|
|
• adult mice treated with tamoxifen beginning at 3 months of age develop severe polycystic kidney disease that is more severe in males despite similar recombination efficiencies in both genders
• after 1 month, mice treated with tamoxifen by breast feeding beginning at 4 days of age exhibit more severe polycystic kidney disease then their mothers sacrificed 1 to 5 months after initiation of treatment
|
|
|
• at 5 months, mice treated with tamoxifen beginning at 3 months of age exhibit a kidney to body weight ratio of 2% to 9.5% compared to 1.3% to 1.8% in wild-type mice
|
|
|
• after 1 months of treatment with tamoxifen beginning at 3 months of age
|
|
|
• at 5 months, mice treated with tamoxifen beginning at 3 months of age exhibit pale kidneys
|
liver/biliary system
|
|
• by 4 to 11 months of age mice treated with tamoxifen beginning at 3 months of age develop liver cysts
|
cellular
|
|
• adult mice treated with tamoxifen for 3 to 5 months exhibit a 5- to 20-fold increase in proliferation index for precystic tubular epithelial cells compared to wild-type mice
|
growth/size/body
|
|
• mice exhibit 1-5 cysts after 1 months of treatment with tamoxifen beginning at 3 months of age and about 10 cysts after 3 months that are bilateral and in the cortex and medulla
• mice develop massive cysts 1 month after exposure to tamoxifen by breast feeding beginning at 4 days of age that arise from distal parts of the nephron and are uromodulin-positive
|
|
|
• adult mice treated with tamoxifen beginning at 3 months of age develop severe polycystic kidney disease that is more severe in males despite similar recombination efficiencies in both genders
• after 1 month, mice treated with tamoxifen by breast feeding beginning at 4 days of age exhibit more severe polycystic kidney disease then their mothers sacrificed 1 to 5 months after initiation of treatment
|
|
|
• by 4 to 11 months of age mice treated with tamoxifen beginning at 3 months of age develop liver cysts
|
|
|
• at 5 months, mice treated with tamoxifen beginning at 3 months of age exhibit a kidney to body weight ratio of 2% to 9.5% compared to 1.3% to 1.8% in wild-type mice
|
Analysis Tools